Advances in the management of corticosteroid-induced osteoporosis with bisphosphonates

Clinical Rheumatology

Volumn 26, Issue 4, 2007, Pages 474-484

  Ringe, Johann D ^a   Farahmand, Parvis ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Bisphosphonates; Corticosteroid induced; Intravenous; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; CLODRONIC ACID; CORTICOSTEROID; ETIDRONIC ACID; FLUORIDE SODIUM; IBANDRONIC ACID; METHOTREXATE; PAMIDRONIC ACID; PLACEBO; PREDNISOLONE; PREDNISONE; RISEDRONIC ACID; TILUDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ASTHMA; BONE DENSITY; BONE FRAGILITY; BONE NECROSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMOTION; FRACTURE; FRAGILITY FRACTURE; GASTROINTESTINAL DISEASE; HEALTH CARE COST; HIP FRACTURE; HUMAN; INJECTION SITE REACTION; KIDNEY DISEASE; LONG TERM CARE; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; OSTEOLYSIS; OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK REDUCTION; SIDE EFFECT; SOCIAL ASPECT; SYSTEMATIC REVIEW; UVEITIS; VERTEBRA FRACTURE;

ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS;

EID: 33847688502     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-006-0467-z     Document Type: Review

References (87)

1. American College of Rheumatology Task Force on Osteoporosis (1996) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 39:1791-1801
2. Grotz WH, Mundinger FA, Gugel B, Exner V, Kirste G, Schollmeyer PJ (1994) Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. Transplantation 58:912-915
3. Grotz WH, Mundinger FA, Gugel B, Exner VM, Kirste G, Schollmeyer PJ (1995) Bone mineral density after kidney transplantation: A cross-sectional study in 190 graft recipients up to 20 years after transplantation. Transplantation 59:982-986
4. Leong GM, Center JR, Henderson NK, Eisman JA (2001) Glucocorticoid-induced osteoporosis. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis, vol 2. Academic, San Diego, pp 69-93
5. Hommann H, Abendroth K, Lehmann G, Patzer N, Kornberg A, Voigt R, Seifert S, Hein G, Scheele J (2002) Effect of transplantation on bone: osteoporosis after liver and multivisceral transplantation. Transplant Proc 34:2296-2298
6. Compston JE (2003) Osteoporosis after liver transplantation. Liver Transplant 9:321-330
7. Giannini S, D'Angelo A, Carraro G, Antonello A, Di Landro D, Marchini F, Plebani M, Zaninotto M, Rigotti P, Sartori L, Crepaldi G (2001) Persistently increased bone turnover and low bone density in long-term survivors to kidney transplantation. Clin Nephrol 56:353-363
8. Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, Hosking DJ, Purdie DW, Ralston SH, Reeve J, Russell RG, Stevenson JC, Torgerson DJ (1998) A UK Consensus Group on management of glucocorticoid-induced osteoporosis: An update. J Intern Med 244:271-292
9. de Nijs RNJ, Jacobs JW, Bijlsma JW, Lems WF, Laan RF, Houben HH, ter Borg EJ, Huisman AM, Bruyn GA, van Oijen PL, Westgeest AA, Algra A, Hofman DM (2001) Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis. Rheumatology 40:1375-1383
10. Blake GM, Fogelman I (2002) Bone densitometry, steroids and osteoporosis. Curr Opin Nephrol Hypertens 11:641-647
11. Scane AC, Francis RM, Sutcliffe AM, Francis MJ, Rawlings DJ, Chapple CL (1999) Case-control study of the pathogenesis and sequelae of symptomatic vertebral fractures in men. Osteoporos Int 9:91-97
12. Cooper C, Coupland C, Mitchell M (1995) Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 54:49-52
13. Lukert BP, Raisz LG (1990) Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 112:325-364
14. Haagsma EB, Thijn CJ, Post JG, Slooff MJ, Gips CH (1998) Bone disease after orthotopic liver transplantation. J Hepatol 6:94-100
15. Riemens SC, Oostdijk A, van Doormaal JJ, Thijn CJ, Drent G, Piers DA, Groen EW, Meerman L, Slooff MJ, Haagsma EB (1996) Bone loss after liver transplantation is not prevented by cyclical etidronate, calcium and alphacalfidol. The Liver Transplant Group, Groningen. Osteoporos Int 6:213-218
16. Kanis JA, Pitt FA (1992) Epidemiology of osteoporosis. Bone 13(Suppl 1):S7-15
17. International Osteoporosis Foundation (2003) Osteoporosis in the European community: ActHon plan. Available from: http://www.osteofound.org/advocacy_policy/eu_policy_project/pdf/ action_plan_03_e.pdf. Accessed February 7, 2005
18. American College of Rheumatology ad hoc committee on glucocorticoid-induced osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. 2001 Update. Arthritis Rheum 44:1496-1503
19. Yeap SS, Hosking DJ (2002) Management of corticosteroid-induced osteoporosis. Rheumatology 41:1088-1094
20. van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C (2000) Use of oral corticosteroids in the United Kingdom. QJM 93:105-111
21. Hougardy DM, Peterson GM, Bleasel MD, Randall CT (2000) Is enough attention being given to the adverse effects of corticosteroid therapy? J Clin Pharm Ther 25:227-234
22. Russell RGG, Croucher PI, Rogers MJ (1999) Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 9(Suppl 2):S66-S80
23. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T (1999) Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104:1363-1374
24. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, Yanover MJ, Mysiw WJ, Kohse L, Rao B, Steiger P, Richmond B, Chesnut CH (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73-79
25. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541
26. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352
27. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333-340
28. Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241-1249
29. Amin S, Lavalley MP, Simms RW, Felson DT (2002) The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: A meta-regression. J Bone Miner Res 17:1512-1526
30. Homik JE, Cranney A, Shea B, Tugwell P, Wells G, Adachi JD, Suarez-Almazor ME (1999) A meta-analysis on the use of bisphosphonates in corticosteroid induced osteoporosis. J Rheumatol 26:1148-1157
31. Blair MM, Carson DS, Barrington R (2000) Bisphosphonates in the prevention and treatment of glucocorticoid-induced osteoporosis. J Fam Pract 49:839-848
32. Miller PD (2001) Bisphosphonates for the prevention and treatment of corticosteroid-induced osteoporosis. Osteoporos Int 12(Suppl 3):S3-S10
33. Adachi JD, Papaioannou A (2001) Corticosteroid-induced osteoporosis: detection and management. Drug Safety 24:607-624
34. Pols HA, Wittenberg J (2002) CBO guideline 'Osteoporosis' (second revision). Ned Tijdschr Geneeskd 146:1359-1363
35. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MO, Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis A (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum 44:202-211
36. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA (1999) Risedronate therapy prevents corticosteroid-induced bone loss: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42:2309-2318
37. Eastell R, Devogelaer JP, Peel NF, Chines AA, Bax DE, Sacco-Gibson N, Nagant de Deuxchaisnes C, Russell RG (2000) Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 11:331-337
38. Gonnelli S, Rottoli P, Cepollaro C, Pondrelli C, Cappiello V, Vagliasindi M, Gennari C (1997) Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int 61:382-385
39. Lau EMC, Woo J, Chan YH, Li M (2001) Alendronate for the prevention of bone loss in patients on inhaled steroid therapy. Bone 29:506-510
40. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292-299
41. Yilmaz L, Ozoran K, Gunduz OH, Ucan H, Yucel M (2001) Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids. Rheumatol Int 20:65-69
42. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA (1997) Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337:382-387
43. Roux C, Oriente P, Laan R, Hughes RA, Ittner J, Goemaere S, Di Munno O, Pouilles JM, Horlait S, Cortet B (1998) Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group. J Clin Endocrinol Metab 83:1128-1133
44. Shane E, Addesso V, Namerow PB, McMahon DJ, Lo SH, Staron RB, Zucker M, Pardi S, Maybaum S, Mancini D (2004) Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 350:767-776
45. Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. European corticosteroid-induced osteoporosis treatment study. J Bone Miner Res 15:1006-1013
46. Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F (2003) Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: Results from a long-term comparative study. Osteoporos Int 14:801-807
47. Adami S, Zamberlan N (1996) Adverse effects of bisphosphonates. A comparative review. Drug Safety 14:158-170
48. Boyce BF, Smith L, Fogelman I, Johnston E, Ralston S, Boyle IT (1984) Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet 1:821-824
49. Jenkins EA, Walker-Bone KE, Wood A, McCrae FC, Cooper C, Cawley MI (1999) The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate. Scand J Rheumatol 28:152-156
50. Struys A, Snelder AA, Mulder H (1995) Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 99:235-242
51. Lems WF, Jacobs JW, Bijlsma JW, van Veen GJ, Houben HH, Haanen HC, Gerrits MI, van Rijn HJ (1997) Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis? Ann Rheum Dis 56:357-363
52. Sebaldt RJ, Ioannidis G, Adachi JD, Bensen WG, Bianchi F, Cividino A, Gordon M, Kaminska E, Scocchia T, Petrie A, Stephenson GF, Goldsmith CH (1999) 36 month intermittent cyclical etidronate treatment in patients with established corticosteroid induced osteoporosis. J Rheumatol 26:1545-1549
53. Arlen DJ, Lambert K, Ionnanidis G, Adachi JD (2001) Treatment of established bone loss after renal transplantation with etidronate. Transplantation 71:669-673
54. Sato S, Ohosone Y, Suwa A, Yasuoka H, Nojima T, Fujii T, Kuwana M, Nakamura K, Mimori T, Hirakata M (2003) Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year follow up. J Rheumatol 30:2673-2679
55. Loddenkemper K, Grauer A, Burmester GR, Buttgereit F (2003) Calcium, vitamin D and etidronate for the prevention and treatment of corticosteroid-induced osteoporosis in patients with rheumatic disease. Clin Exp Rheumatol 21:19-26
56. Sambrook PN, Kotowicz M, Nash P, Styles CB, Naganathan V, Henderson-Briffa KN, Eisman JA, Nicholson GC (2003) Prevention and treatment of glucocorticoid-induced osteoporosis: A comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 18:919-924
57. Jeffery JR, Leslie WD, Karpinski ME, Nickerson PW, Rush DN (2003) Prevalence and treatment of decreased bone density in renal transplant recipients: A randomized prospective trial of calcitriol versus alendronate. Transplantation 76:1498-1502
58. Torregosa JV, Moreno A, Gutierrez S, Vidal S, Oppenheimer F (2003) Alendronate for treatment of renal transplant patients with osteoporosis. Transplant Proc 35:1393-1395
59. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67:277-285
60. Reginster JY, Lecart MP (2004) Treatment of osteoporosis with bisphosphonates: Do compliance and persistence matter? Business briefing: Long-term healthcare 1-6
61. Miller NH (1997) Compliance with treatment regimens in chronic asymptomatic disease. Am J Med 102:43-49
62. Reginster J-Y (2005) Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: A comprehensive review. Curr Pharm Des 11:3711-3728
63. Miller PD (2005) Optimising postmenopausal osteoporosis management with bisphosphonates: The emerging role of intermittent therapy. Clin Ther 27:361-376
64. Bauss F, Russell RGG (2004) Ibandronate in osteoporosis: Preclinical data and rationale for intermittent dosing. Osteoporos Int 15:423-433
65. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653-661
66. Boutsen Y, Jamart J, Esselinckx W, Stoffel M, Devogelaer JP (1997) Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: A randomized trial. Calcif Tissue Int 61:266-271
67. Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP (2001) Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: A prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 16:104-112
68. Gallacher SJ, Fenner JA, Anderson K, Bryden FM, Banham S, Logue FC, Cowan RA, Boyle IT (1992) Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: An open pilot study. Thorax 47:932-936
69. Gallacher SJ, Ralston SH, Patel U, Boyle IT (1989) Side effects of pamidronate. Lancet 2:42-43
70. Rey J, Daumen-Legre V, Pham T, Bernard P, Dahan L, Aquaviva PC, Lafforque P (2000) Uveitis, an under-recognized adverse effect of pamidronate. Case report and literature review. Jt Bone Spine 67:337-340
71. Bounameaux HM, Schifferli J, Montani JP, Jung A, Chatelanat A (1983) Renal failure associated with intravenous diphosphonates. Lancet 1:471
72. Dumon JC, Magritte A, Body JJ (1991) Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcaemia. Bone Miner 15:257-266
73. O'Sullivan TL, Akbari A, Cadnapaphornchai P (1994) Acute renal failure associated with the administration of parenteral etidronate. Ren Fail 16:767-773
74. Chang JT, Green L, Beitz J (2003) Renal failure with the use of zoledronic acid. N Engl J Med 349:1676-1679
75. Markowitz GS, Fine PL, Stack JL, Kunis CL, Radhakrishnan J, Palecki W, Park J, Nasr SH, Hoh S, Siegel DS, D'Agati VD (2003) Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64:281-289
76. Shane E, Goldring S, Christakos S, Drezner M, Eisman J, Silverman S, Pendrys D (2006) EdiMorial: Osteonecrosis of the jaw: more research needed. J Bone Miner Res 21:1503-1505
77. Grotz WH, Nagel C, Poeschel D, Cybulla M, Petersen KG, Uhl M, Strey C, Kirste G, Olschewski M, Reichelt A, Rump LC (2001) Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 12:1530-1537
78. Fahrleitner A, Prenner G, Leb G, Tscheliessnigg K, Piswanger-Sölkner C, Dobnig Hl (2001) Combination therapy with ibandronate and calcitriol is effective in patients following liver transplantation. J Bone Miner Res 16(Suppl 1):ABstract SA364
79. Stakkestad JA, Benevolenskaya LI, Stepan JJ, Skag A, Nordby A, Oefjord E, Burdeska A, Jonkanski I, Mahoney P (2003) Intravenous ibandronate injections given every three months: A new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis 62:969-975
80. Recker RR, Reid DM, Sambrook P, Hughes C, Ward P, Bonvoisin B, Adami S (2004) Intermittent intravenous ibandronate injection regimens provide at least equivalent efficacy to daily oral ibandronate: 1-year results from DIVA. Arthritis Rheum 50(Suppl):4095
81. Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209-216
82. Hamilton B, McCoy K, Taggart H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 14:259-262
83. Reid DM, Felsenberg D, Christiansen C, Leigh C, Ward P, Sedarati F, Delmas PD (2005) Favourable renal safety and tolerability profile of intravenous ibandronate injections in women with postmenopausal osteoporosis: 1-year results from DIVA. Ann Rheum Dis 64(Suppl 3):365 (Abstract FRI0362)
84. Thiébaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, Schoter KH (1997) Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 103:298-307
85. Recker R, Stakkestad JA, Chesnut CH, Christiansen C, Skag A, Hoiseth A, Ettinger M, Mahoney P, Schimmer RC, Delmas PD (2004) Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34:890-899
86. Adami S, Felsenberg D, Christiansen C, Robinson J, Lorenc RS, Mahoney P, Coutant K, Schimmer RC, Delmas PD (2004) Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 34:881-889
87. Pecherstorfer M, Diel IJ (2004) Rapid administration of ibandronate does not affect renal functioning: Evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy. Support Care Cancer 12:877-881